225 related articles for article (PubMed ID: 22150085)
1. Placental origins of angiogenic dysfunction in mirror syndrome.
Bixel K; Silasi M; Zelop CM; Lim KH; Zsengeller Z; Stillman IE; Rana S
Hypertens Pregnancy; 2012; 31(2):211-7. PubMed ID: 22150085
[TBL] [Abstract][Full Text] [Related]
2. Angiogenic and antiangiogenic factors before and after resolution of maternal mirror syndrome.
Llurba E; Marsal G; Sanchez O; Dominguez C; Alijotas-Reig J; Carreras E; Cabero L
Ultrasound Obstet Gynecol; 2012 Sep; 40(3):367-9. PubMed ID: 22081513
[TBL] [Abstract][Full Text] [Related]
3. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion.
Soto E; Romero R; Kusanovic JP; Ogge G; Hussein Y; Yeo L; Hassan SS; Kim CJ; Chaiworapongsa T
J Matern Fetal Neonatal Med; 2012 May; 25(5):498-507. PubMed ID: 21867402
[TBL] [Abstract][Full Text] [Related]
4. Placental expression of anti-angiogenic proteins in mirror syndrome: a case report.
Graham N; Garrod A; Bullen P; Heazell AE
Placenta; 2012 Jun; 33(6):528-31. PubMed ID: 22401877
[TBL] [Abstract][Full Text] [Related]
5. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
Govender N; Naicker T; Rajakumar A; Moodley J
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
[TBL] [Abstract][Full Text] [Related]
7. Increased concentrations of antiangiogenic factors in mirror syndrome complicating twin-to-twin transfusion syndrome.
Prefumo F; Pagani G; Fratelli N; Benigni A; Frusca T
Prenat Diagn; 2010 Apr; 30(4):378-9. PubMed ID: 20127899
[No Abstract] [Full Text] [Related]
8. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women.
Moore Simas TA; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Maynard SE
J Matern Fetal Neonatal Med; 2014 Jul; 27(10):1038-48. PubMed ID: 24066977
[TBL] [Abstract][Full Text] [Related]
9. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
[TBL] [Abstract][Full Text] [Related]
10. Maternal, gestational and neonatal characteristics and maternal angiogenic factors in normotensive pregnancies.
Staff AC; Harsem NK; Braekke K; Hyer M; Hoover RN; Troisi R
Eur J Obstet Gynecol Reprod Biol; 2009 Mar; 143(1):29-33. PubMed ID: 19135290
[TBL] [Abstract][Full Text] [Related]
11. Angiogenic biomarkers in pregnancy: defining maternal and fetal health.
Rasmussen LG; Lykke JA; Staff AC
Acta Obstet Gynecol Scand; 2015 Aug; 94(8):820-32. PubMed ID: 25753566
[TBL] [Abstract][Full Text] [Related]
12. Gestational angiogenic biomarker patterns in high risk preeclampsia groups.
Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA
Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919
[TBL] [Abstract][Full Text] [Related]
13. Angiogenic imbalance and plasma lipid alterations in women with preeclampsia from a developing country.
Reyes LM; García RG; Ruiz SL; Broadhurst D; Aroca G; Davidge ST; López-Jaramillo P
Growth Factors; 2012 Jun; 30(3):158-66. PubMed ID: 22486210
[TBL] [Abstract][Full Text] [Related]
14. Levels of antiangiogenic factors in preeclamptic pregnancies.
Zhao W; Qiao J; Zhang Q; Zhao Y; Chen Q
Growth Factors; 2010 Aug; 28(4):293-8. PubMed ID: 20214506
[TBL] [Abstract][Full Text] [Related]
15. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.
Aggarwal PK; Chandel N; Jain V; Jha V
J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568
[TBL] [Abstract][Full Text] [Related]
16. Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia.
Leaños-Miranda A; Campos-Galicia I; Ramírez-Valenzuela KL; Chinolla-Arellano ZL; Isordia-Salas I
Hypertension; 2013 May; 61(5):1118-25. PubMed ID: 23460287
[TBL] [Abstract][Full Text] [Related]
17. [New insights in the pathophysiology of preeclampsia and potential therapeutic implications].
Boulanger H; Flamant M
Nephrol Ther; 2007 Dec; 3(7):437-48. PubMed ID: 18047998
[TBL] [Abstract][Full Text] [Related]
18. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia.
De Vivo A; Baviera G; Giordano D; Todarello G; Corrado F; D'anna R
Acta Obstet Gynecol Scand; 2008; 87(8):837-42. PubMed ID: 18607829
[TBL] [Abstract][Full Text] [Related]
19. Explaining and predicting preeclampsia.
Lindheimer MD; Umans JG
N Engl J Med; 2006 Sep; 355(10):1056-8. PubMed ID: 16957153
[No Abstract] [Full Text] [Related]
20. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles.
Alahakoon TI; Zhang W; Trudinger BJ; Lee VW
J Matern Fetal Neonatal Med; 2014 Dec; 27(18):1854-9. PubMed ID: 24397483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
